Reprogramming the Metabolome: How Antibiotic Exposure Drives Obesity and Metabolic Phenotypes via Gut Microbiota Dysbiosis

Obesity and associated metabolic disorders, including type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), constitute escalating global public health challenges. While high-fat diets and genetic predispositions are established drivers, the human gut microbiota has emerged as a fundamental regulator of host energy expenditure, adiposity, and immune homeostasis. Antibiotics are among the most frequently administered antimicrobial agents worldwide, yet their clinical and environmental exposure serves as a major driver of gut microbial dysbiosis.

Published in Frontiers in Microbiology, this comprehensive review systematically evaluates how antibiotic exposure reprograms host metabolic phenotypes through gut microbiota perturbations. Although prior literature linked antimicrobial administration to altered microbial composition, critical research gaps remained regarding how specific antibiotic classes, dosage regimens, and developmental exposure windows differentially modulate host metabolic pathways. This review addresses these gaps by synthesizing epidemiological data, animal model mechanistic experiments, and multi-omics findings to map the biochemical cascade connecting antibiotic usage to metabolic disease.

Highlights

• Distinct Class-Specific Ecological Signatures: Categorizes antibiotic classes by their differential impact, distinguishing persistent structural disruptions caused by macrolides and fluoroquinolones from transient impacts of certain beta-lactams.
• Developmental Window and Dose Dependency: Demonstrates that low-dose early-life exposure promotes lipid storage via microbiome reprogramming, whereas high-dose microbial depletion in adulthood yields markedly different metabolic outcomes.
• Integrated Multi-Omics Pathway Profiling: Synthesizes metagenomic, Metabolomic, and transcriptomic evidence to map key biochemical pathways, including short-chain fatty acid (SCFA) depletion, Farnesoid X Receptor (FXR) axis disruption, and phenyllactic acid (PLA) signaling suppression.
• Resistome-Microbiome Dissociation: Identifies a critical phenomenon where taxonomic community structure partially recovers post-antibiotic cessation, yet antimicrobial resistance genes (ARGs) and functional metabolic alterations persist long-term.

Key Findings

• Epidemiological Evidence and Exposure Dynamics

Epidemiological studies establish that antibiotic-associated obesity risk depends on exposure timing, cumulative dosage, and antimicrobial spectrum. A multicenter case-control study demonstrated that school-aged children exposed to antibiotics, particularly florfenicol from environmental or food-chain sources, exhibited a significantly elevated risk of overweight or obesity. Environmental monitoring confirmed that elevated urinary concentrations of tetracycline and sulfamethoxazole positively correlated with childhood obesity risk, showing pronounced effects even at low-to-moderate exposure levels. Furthermore, cohort data established a clear dose-response relationship: higher cumulative antibiotic classes, increased exposure frequency, and earlier age at first exposure directly correlated with higher childhood body mass index (BMI) and obesity incidence.

As summarized in Tab.1, consequences vary substantially across antibiotic classes:

• Beta-lactams (e.g., penicillin, amoxicillin, cephalosporins): Target cell wall synthesis. Low-dose early-life exposure perturbs bacterial and phage communities, depletes early colonizers such as Lactobacillus, and alters intestinal lipid signaling to promote adiposity.
• Tetracyclines (e.g., chlortetracycline, doxycycline): Inhibit the 30S ribosomal subunit. Subtherapeutic exposure restructures gut communities and alters SCFA metabolism, increasing fat mass without a uniform taxonomic signature.
• Macrolides (e.g., azithromycin, tylosin): Inhibit the 50S ribosomal subunit. They induce structural perturbations persisting for years, directly inhibit brown/beige adipocyte thermogenesis, promote lipid accumulation, and elevate obesity risk.
• Fluoroquinolones (e.g., ciprofloxacin): Inhibit DNA gyrase and topoisomerase IV. They induce rapid reductions in alpha diversity, extensive community restructuring, and expansion of the gut resistome.

Tab.1 Microbiome and metabolic effects of different antibiotic classes. (Zhu, et al., 2026)

• Experimental Causal Proof and Molecular Signaling Cascades

Animal models confirm direct causality. Experimental studies demonstrated that subtherapeutic penicillin, vancomycin, or chlortetracycline administration in young mice increased fat mass and shifted SCFA ratios without decreasing total bacterial density. Further research showed that low-dose penicillin during pregnancy or weaning induced persistent fat accumulation; transplanting this perturbed microbiota into germ-free recipient mice transferred the adiposity phenotype.

At the molecular level, mechanistic studies showed that early-life low-dose penicillin reduced Lactobacillus murinus, decreasing its metabolite PLA in the small intestine. Under high-fat diet conditions, PLA depletion suppressed epithelial peroxisome proliferator-activated receptor gamma (PPARγ) signaling, enhancing lipid absorption and weight gain—an effect eliminated by intestinal epithelial PPARγ knockout. Additionally, macrolides like azithromycin directly impair mitochondrial respiration and downregulate thermogenic markers, including uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), in brown and beige adipocytes while elevating reactive oxygen species (ROS) generation.

• The Cascade of Dysbiosis, Endotoxemia, and Insulin Resistance

Antibiotic exposure triggers a multi-step metabolic cascade. Decreased SCFA production (particularly butyrate and propionate) compromises colonocyte energy, weakening tight junctions and increasing intestinal permeability. Translocated lipopolysaccharides (LPS) induce metabolic endotoxemia and activate toll-like receptors (TLRs) on immune cells, initiating the nuclear factor kappa B (NF-κB) inflammatory cascade.

This systemic inflammation elevates cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). In liver and adipose tissue, these mediators induce serine phosphorylation of insulin receptor substrate 1 (IRS-1), directly disrupting downstream insulin signaling and causing systemic insulin resistance. Dysbiosis also enriches families such as Lachnospiraceae, causing luminal accumulation of host-accessible monosaccharides that further drive lipid storage and inflammation. Concurrent disruption of the bile acid-FXR and TGRa5 signaling axis impairs hepatic fatty acid oxidation and glucose tolerance.

Fig.1 Impact of antibiotics on obesity-related metabolic outcomes via gut microbiota modulation. (Zhu, et al., 2026)

• Early-Life Vulnerability, Immunity, and Resistome Persistence

Infancy represents a critical window for gut microbiome maturation. A prospective cohort study of 5,128 children revealed that recurrent antibiotic exposure within the first 12 months of life significantly increased BMI and obesity risk at age 4.5 years. Sequencing confirms that early exposure reduces beneficial taxa (Bifidobacterium, Lactobacillus) while expanding opportunistic Proteobacteria and Enterobacteriaceae. Early exposure also suppresses colonic regulatory T cells (Tregs) and downregulates ileal immune expression pathways, impairing intestinal immune maturation.

Metagenomic evidence demonstrates that antibiotic exposure expands ARGs under selective pressure. Clinical and cohort studies show that antibiotic administration or cesarean delivery significantly elevates infant ARG burdens. Crucially, even after taxonomic composition partially recovers post-treatment, ARGs remain elevated long-term, highlighting a clear dissociation between microbial structural recovery and persistent resistance traits.

Research Approaches & Support

Further investigation of gut microbiota dysbiosis, metabolic phenotypes, and microbiome-based interventions requires integrated approaches combining microbial profiling, metabolic characterization, and translational validation. Protheragen supports these efforts through comprehensive preclinical microbiome and multi-omics capabilities, including high-throughput metagenomic sequencing, targeted metabolomics for short-chain fatty acids and bile acids, customized germ-free and microbiome-associated mouse models, and advanced bioinformatics workflows. These integrated approaches enable researchers to characterize microbiome–host interactions, identify metabolic signatures, and evaluate potential therapeutic strategies for metabolic disease research.

Interpretation & Translational Value

This review demonstrates that antibiotic exposure acts as a potent external modifier of host metabolic health through gut microbiota restructuring, barrier impairment, metabolite depletion, and systemic inflammation. These findings emphasize the necessity of rigorous antibiotic stewardship during early developmental windows and highlight the potential of targeted microecological interventions, such as strain-specific probiotics (Lactobacillus plantarum L11 or Lactobacillus reuteri LR via AMPK activation), synbiotics, and metabolite replenishment (PLA, butyrate, propionate), to mitigate antibiotic-induced metabolic disorders.